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mation to the surgeon which enables a more detailed op-
eration planning, and it is a valuable diagnostic modality for 
patients with PHPT in our opinion. We hope that our data 
encourage other centers to implement this technique as 
well.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Primary hyperparathyroidism (PHPT) is most often 
due to one parathyroid adenoma secreting excessive 
parathyroid hormone (PTH)  [1] . These patients are char-
acterized by a persistent hypercalcemia with a concomi-
tant increase or inappropriately high level of serum 
PTH. The standard of care for PHPT is surgical removal 
of all hyperfunctioning parathyroid tissue. In experi-
enced hands, parathyroidectomy by conventional neck 
exploration (CNE) is successful in 95–99%, with a very 
low complication rate  [2, 3] . However,  1 90% of the pa-
tients have only one abnormal parathyroid gland, which 
makes it suitable for a focused approach (minimally in-
vasive parathyroidectomy, MIP). Large studies have 
compared CNE with the minimally invasive approach 
(MIA) showing equal cure and complication rates  [4–7] . 
The latter has the potential to be more cost effective with 
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 Abstract 
 Background: Minimally invasive parathyroidectomy is the 
treatment of choice for single-gland primary hyperparathy-
roidism. However, the exact location of the abnormal gland 
has to be established. Sestamibi scintigraphy, computed to-
mography and ultrasound (US) are commonly used modali-
ties. We describe our experience in a non-academic center 
with surgeon-performed US (S-US) of the neck as preopera-
tive localization study in patients with primary hyperpara-
thyroidism (PHPT).  Methods: Patients with a biochemically 
proven diagnosis of PHPT and preoperative S-US were in-
cluded. Data were recorded prospectively. Perioperative 
gland location was compared to the preoperative S-US to 
determine sensitivity, specificity and accuracy rates.  Results: 
Two of the 50 patients who underwent S-US were not sub-
jected to surgery. In 85% of the patients analyzed by S-US, 
the appropriate abnormal gland(s) were identified. In 11%, 
no gland was identified, but abnormal glands were found 
during surgery. Sensitivity of S-US in our hospital is 85%, with 
a positive predictive value of 97%.  Conclusions: We achieved 
a satisfactory sensitivity rate. S-US provides anatomic infor-
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a shorter operation time and a shorter hospitalization 
 [8] . Nowadays, MIP is the standard of care in case of uni-
glandular PHPT with preoperatively localized disease. 
Once the biochemical diagnosis of PHPT is established, 
preoperative localization of the abnormal glands is the 
next step towards MIP. Various imaging modalities can 
be used to identify the diseased glands. Technetium 
99m-sestamibi scintigraphy (MIBI), which is commonly 
used, is based on a difference in absorption of sestamibi 
between normal and hyperfunctioning glands. The ac-
curacy of MIBI depends on the particular scanning 
technique used  [9] , and reported sensitivity rates range 
from 54 to 88%  [10, 11] . Sestamibi scintigraphy is repro-
ducible and investigator independent, and abnormal 
parathyroid glands are relatively easy to detect. The scan 
does not allow precise anatomical localization, and only 
roughly indicates at which side and level of the neck the 
lesion is situated. 
 Computed tomography (CT) provides high-quality 
two (sometimes three)-dimensional anatomical images 
and has a reported  sensitivity of 66% and  specificity of 
89%  [12] . It is possible to use positron emission tomogra-
phy in combination with CT to detect the hyperfunction-
ing gland, but this is not yet widely implemented  [13] . 
Magnetic resonance imaging is another possible imaging 
modality with a reported sensitivity rate of 43.4–57.1% 
 [14, 15] . Ultrasound (US) is quick, non-invasive and does 
not require the use of radioactive materials. Unfortunate-
ly, US is highly operator dependent  [16] and much infor-
mation is lost when the two-dimensional images are 
stored. US performed by radiologists (R-US) have report-
ed sensitivity rates of 59–96%  [11, 17] . An increasing 
number of surgeons are using US as an extension of the 
clinical examination (surgeon-performed US, S-US). The 
use of office-based S-US  to localize abnormal parathy-
roid glands preoperatively is not new. In several pub-
lished studies, sensitivity rates of 66–76% have been re-
ported  [18–20] .
 The majority of data on S-US published in the last 
years were collected from university hospitals and refer-
ral centers. Results from non-academic hospitals remain 
scarce, which gives the impression that S-US is a modal-
ity which is mainly performed in an academic setting. 
Whether S-US measurements are useful in a non-aca-
demic hospital setting, usually treating a lower number 
of patients, remains obscure. The aim of this study is to 
describe the experience in performing S-US as an addi-
tional preoperative localization study in patients with 
PHPT in a non-academic center.
 Materials and Methods 
 Data were collected at the Reinier de Graaf Hospital from Au-
gust 2004 till September 2008. Before 2005, medical records of the 
participating patients were retrieved using operation-specific 
codes and relevant hospital coding systems. Thereafter, results 
were collected prospectively. All patients with a biochemically 
proven diagnosis of PHPT who were scheduled to undergo sur-
gery underwent a preoperative US performed by the dedicated 
surgeon and were included in the analysis. Baseline characteris-
tics (gender, age and preoperative laboratory values) were collect-
ed. All patients received preoperative localization studies consist-
ing of MIBI and/or US investigation (R-US and/or S-US) and/or 
CT. MIBI and CT scans were performed using similar settings 
(slice thickness, timing and amount of radioactive material) dur-
ing the whole study period.
 Surgeon-Performed Ultrasonography 
 One of our endocrine surgeons (P.C.S.) performs neck US 
(Philips Envisor HD) at the outpatient clinic since 2004. No S-US 
were performed in the operating room just prior to surgery. The 
linear ray probe with a frequency of 3–12 MHz is used with the 
software set on thyroid modus. The patient is examined in supine 
position with the neck in hyperextension. US provides an image of 
the entire neck, from the angles of the jaw to the sternal notch. 
When the probe is aimed downwards, the upper mediastinum can 
be visualized. However, the retrocervical tracheal space cannot be 
studied by ultrasound as the air in the trachea hinders the passage 
of the ultrasound waves. Previous neck surgery, radiation therapy 
and goiter negatively affect US. When a possible enlargement of 
the parathyroid gland was identified, color Doppler US was used 
to determine the vascularity of the lesion to identify a vascular 
pedicle strengthening the diagnosis of a parathyroid adenoma. 
Parathyroid adenomas were defined as any oval, elongated, or lob-
ulated lesion connected with the thyroid gland during swallowing 
without a central hilum (characteristic for a lymph node). Lesions 
with the same characteristics but an increased and/or irregular 
reflection pattern, cystic changes and/or calcifications represent-
ing degeneration and measuring from 1–2 to   5 cm in length were 
also considered to be an adenoma. When the solitary adenoma was 
located posterior to the thyroid lobe near the middle portion, it 
was considered an adenoma of the superior type. It was considered 
an inferior type when it was located near the lower pole of a thyroid 
lobe or inferior to it and having, at least in part, a close relationship 
with the anterior muscular wall of the neck. Any other location 
was considered aberrant. US takes approximately 10–15 min, and 
findings are directly recorded in the patient’s chart, with a detailed 
map (US pictures, drawings and text) for the scheduled surgical 
approach. The location of the future incision is described using the 
midline and the clavicula as landmarks. 
 Surgery 
 All procedures, both conventional neck explorations and MIP, 
were performed under general anesthesia by one of the two dedi-
cated endocrine surgeons, either P.W.d.G. or P.C.S. P.C.S., who 
also performed S-US, carried out  1 80% of the operations. The 
MIP, consisting of a small incision ( ! 3 cm) above the suspect 
gland, was the operation of choice for single-gland disease. PTH 
levels were assessed intraoperatively to support the success of the 
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pocalcemic patients with normal PTH levels were considered 
cured. Persistent disease was defined as persistent hypercalcemia 
in the first 3 months after surgery. Recurrent disease was defined 
as hypercalcemia returning later than 3 months postoperatively. 
Serum calcium levels were obtained the evening after surgery, the 
next day and during visits at the outpatient clinic. These visits 
were planned approximately 2 weeks postoperatively at the De-
partment of Surgery, and 3 and 12 months after surgery at the 
Department of Endocrinology. In case of temporary hypocalce-
mia, calcium supplementation was prescribed. 
 Statistical Analysis 
 Only descriptive statistics are used. Data were tested for nor-
mality using the Shapiro-Wilk test and visual assessment. Normal-
ly distributed data are presented as means  8 SD. Non-normally 
distributed data are reported as medians and ranges. For each im-
aging modality, any gland that was identified as abnormal parathy-
roid tissue by imaging. and confirmed as such by operative findings 
was scored as true positive (TP). A finding was false positive (FP) 
if operative findings did not confirm an abnormality of the gland 
detected by imaging. A finding was true negative (TN) if the gland 
was identified as normal by imaging and this was confirmed by 
intra-operative PTH levels and operative findings (among patients 
who underwent bilateral neck exploration). A finding was false 
negative (FN) if S-US failed to identify the abnormal gland but an 
abnormality was detected during the operation. Sensitivity was de-
fined as TP/(TP + FN), specificity was defined as TN/(TN + FP), 
positive predictive value was defined as TP/(TP + FP), and negative 
predictive value was defined as TN/(TN + FN). The S-US localiza-
tion was scored correct if the imaging technique predicted the 
proper quadrant (namely, upper left, upper right, lower left or low-
er right). The prediction was compared to the ‘gold standard’, 
which is for abnormal glands perioperative surgical findings com-
bined with an abnormal gland during pathological analysis [abnor-
mal glands include: adenomas (characterized by a neoplastic 
monoclonal process), hyperplastic glands (characterized by a poly-
clonal proliferation) or unsure (adenoma or hyperplasia)]. A cured 
patient indicates that there is no abnormal tissue left and all ‘abnor-
mal’ glands have been removed, thus rendering the difference be-
tween adenoma and hyperplasia less important in this study. For 
normal glands, the prediction was compared to the pathological 
analysis or, if the gland remained in situ, a cured patient. Therefore, 
uncured patients are left out of this part of the analysis. 
 Results 
 From August 2004 until September 2008, 50 patients 
were included in the study. The analysis comprised 33 
(66%) women and 17 (34%) men, with a median age of 58 
years (range 20–82). The preoperative median serum cal-
cium level was 2.79 mmol/l (range 2.56–3.26, normal 
range 2.20–2.60) and the median serum PTH level was 
12.40 pmol/l (range 5.6–70.4, normal range 1.0–5.5). One 
patient had (high) normal calcium levels under calcium-
lowering medication (PTH = 8.6). All other patients were 
hypercalcemic.
 Surgery 
 In 2 patients, it was decided to refrain from surgery 
due to the mild character of the disease combined with 
high comorbidity of the patients. They were excluded 
from further analysis. Forty-four patients underwent a 
first surgical procedure for PHPT. The MIP was chosen 
in 38 patients (86%); 6 patients (14%) underwent CNE. 
Reasons for CNE were multiple gland disease, recurrent 
nerve paresis due to unknown etiology, unequivocal im-
aging results or no reason specified.
 In 4 patients, only the second operations for persistent 
hypercalcemia (reoperation) are included in the study, as 
the first operations were performed prior to the start of 
our study. Two patients could be cured by means of MIP. 
The other 2 patients are discussed in more detail as they 
had persistent disease. One patient developed recurrent 
disease after surgery in 1979. The patient was operated by 
means of a targeted approach to the left lower parathy-
roid, based on the results of the sestamibi scan. As intra-
operative PTH levels failed to decrease, the surgical pro-
cedure was converted to a conventional neck operation. 
No abnormal parathyroid glands were identified. This 
patient was referred to a tertiary center. The last commu-
nication reports that, based on low urinary calcium lev-
els, the diagnosis of hypocalciuric hypercalcemia is con-
sidered. The other patient was also treated for recurrent 
disease years after her first operation. CNE revealed an 
adenoma which was removed from a location different to 
that detected by S-US. This patient has, at the time of re-
porting, a normal calcium level with a high PTH level. 
Regrettably, during follow-up, a malignancy with metas-
tasis (non-parathyroid) was diagnosed in this patient and 
evaluation of the hyperparathyroidism was discontinued.
 Results of Surgeon-Performed Ultrasound 
 In total, 50 US were performed by the surgeon at the 
outpatient department. Four patients were excluded from 
the following analysis as no definite conclusion can be 
made about all 4 parathyroid glands (n = 2, not operated; 
n = 2 not cured). Preoperative S-US identified all the im-
portant anatomical landmarks: namely trachea, esopha-
gus (paraesophageal grove), thyroid gland, carotid artery 
and jugular vein in all patients. All patients underwent 
both MIBI scanning and S-US. A CT scan was performed 
in 20/46 (44%) patients and R-US in 26/46 (57%) patients. 
Results from MIBI, R-US and S-US are shown in  table 1 .
 In 40 of the 46 (87%) S-USs, the suspected lesions seen 
on S-US truly were hyperfunctioning glands, however in 
2 cases multiple-gland disease was overlooked (4%). In 1 
case, multiple-gland disease was adequately predicted. In 
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5 cases (11%), no gland was identified by S-US, while an 
abnormal gland was found during surgery. In 1 patient 
(2%), S-US identified an abnormal gland, but the gland 
was in the wrong quadrant (adequate side of the neck). 
 Follow-Up and Complications 
 The mean calcium level of all cured patients (1-year 
follow-up) was 2.36 mmol/l (range 2.25–2.53, normal 
range 2.20–2.60). Two patients are not considered cured, 
one of them is currently being treated for a metastatic 
disease and the other is diagnosed with hypocalciuric hy-
percalcemia (both are described in the Surgery section).
 Three of the 48 operated patients (6%) had temporary 
postoperative hypocalcaemia for which 1 patient needed 
calcium supplementation. One patient had temporary 
hoarseness, most likely due to irritation by intubation, 
which restored rapidly. A re-operation for hemorrhage 
was needed in 1 patient. 
 Discussion 
 This study encompasses patients with PHPT who un-
derwent preoperative S-US. The aim of our article is to 
describe the experience of US performed in a single non-
academic center by a surgeon. As surgeons become more 
familiar with the use of US, it is more often applied as an 
extension of the physical examination during the initial 
office visit  [20] . This trend is not restricted to parathyroid 
disease, it is also observed in other fields of medicine  [21–
23] . In our opinion, one of the main benefits of S-US is 
the support of sonographic findings prior to and during 
surgical treatment. The knowledge of the exact gland lo-
cation enables the surgeon to perform a targeted tissue 
dissection, thereby possibly decreasing the risk of recur-
rent nerve injury and reducing scar formation. A pro-
spective trial in a large cohort should be conducted to 
determine whether S-US leads to lower complication 
rates and shorter operation times. 
 Although it may require more logistical planning, it 
may be beneficial to perform S-US directly before surgery 
in the operating room. This enables the surgeon to di-
rectly plan the operation and the incision site, without the 
need for ‘remembering’ the case from the outpatient de-
partment. However, if no gland is found and more imag-
ing is needed, the operation needs to be rescheduled. In 
addition, in our hospital, we use S-US as an additional 
imaging modality. We feel that if the S-US shows no ab-
normal glands, the other imaging modalities (MIBI, CT, 
R-US) must show an abnormal gland in order to proceed 
to MIP. Otherwise, CNE must be considered.
 We acknowledge the fact that the number of patients 
in this study is limited and therefore these results should 
be interpreted with care. We also emphasize that it was 
not our intention to compare S-US with R-US, as our data 
were not suitable for this purpose. For example, S-US re-
sults cannot be compared with R-US results as the latter 
have been done by various radiologists, instead of one in-
vestigator. Secondly S-US is most of the times performed 
after the MIBI results were available, whereas some R-US 
were the first imaging modality applied.
 Recent studies have shown US to be highly accurate in 
localizing parathyroid adenomas with reported sensitiv-
ity rates of up to 70–92.5%  [17, 19, 24] . Our sensitivity rate 
is 85%.
 The incidence of multiglandular disease in this study 
was 6%, which is within the normal range, but in the low-
er region of the incidence rates reported in the literature 
 [18, 25–27] . This could be due to the relatively small num-
bers of patients in our study. As previously reported, pre-
operative localization is less accurate in multiglandular 
disease compared to single-gland disease  [26] . The lower 
incidence of multiglandular disease in our study popula-
tion may be a bias towards the results. 
Table 1. R esults of preoperative localization studies
Glands, n TN TP SN SP PPV NPV Accuracy
total abnormal normal
MIBI (n = 46) 184 40 144 135 37 80% 98% 93% 94% 93%
S-US (n = 46) 184 42 142 135 41 85% 99% 98% 95% 96%
R-US (n = 26) 104 14 90 76 13 48% 99% 93% 84% 86%
T P = True positive; SN = sensitivity; TN = true negative; SP = specificity; PPV = positive predictive value; 
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 Several studies suggest that if S-US shows one abnor-
mal gland, no further examination/imaging is needed 
and one may perform MIP  [19] . Our study is not suited to 
draw conclusions regarding this statement. Many S-US 
are performed while knowing the results of the MIBI 
scanning, thus introducing bias. Although we report test 
characteristics of our imaging modalities, we cannot di-
rectly compare them due to the aforementioned bias.
 Altogether, we regard S-US as a unique opportunity 
for the surgeon to plan the operation in detail by means 
of the detailed anatomical information provided by S-US. 
Despite the limitations of US (multiglandular disease/in-
terobserver variety), the benefits (non–invasive approach 
with detailed real-time anatomical information which is 
easy to use) have led us to use S-US in every patient visit-
ing our outpatient clinic and achieve a very acceptable 
sensitivity rate. We recommend the use of S-US and hope 
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